Clelland, Elle N. http://orcid.org/0000-0003-1439-0532
Rothschild, Harriet T. http://orcid.org/0000-0001-5311-2872
Patterson, Anne http://orcid.org/0000-0002-1416-7376
Molina-Vega, Julissa
Kaur, Mandeep http://orcid.org/0000-0002-5544-5918
Symmans, W. Fraser http://orcid.org/0000-0002-1526-184X
Schwartz, Christopher J. http://orcid.org/0000-0002-8086-8429
Chien, A. Jo http://orcid.org/0000-0003-2978-6249
Benz, Christopher C.
Mukhtar, Rita A. http://orcid.org/0000-0001-8079-7846
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (K08CA256047)
Article History
Received: 1 March 2023
Accepted: 16 July 2023
First Online: 27 July 2023
Declarations
:
: Dr. Symmans’ disclosures include Stock and Other Ownership Interests: ISIS Pharmaceuticals, Delphi Diagnostics, Eiger BioPharmaceuticals. Consulting or Advisory Role: Merck, AstraZeneca. Research Funding: Pfizer (Inst). Patents, Royalties, Other Intellectual Property: Co-inventor, US Patent No. 11,459,617 “Targeted Measure of Transcriptional Activity Related to Hormone Receptors,” issued on October 4, 2022 (applicant proprietor: University of Texas MD Anderson Cancer Center). Uncompensated Relationships: Delphi Diagnostics. A. Jo Chien’s disclosures include research funding from Merck, Puma, Amgen, and Seattle Genetics. The remaining authors have no relevant financial or non-financial interests to disclose.
: Our study was approved by University of California San Francisco Institutional Review Board.